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Clinical and physiologic evidence indicates that maximal coronary 
vasodilation is not achieved in a large number of patients with use 
of the standard dose of dipyridamole (0.56 mg/kg body weight 
over 4 min). The feasibility, safety and accuracy of technetium-
99m hexakis 2-methoxy-2-isobutyl isonitrile (Sestamibi) scintigra-
phy associated with intravenous high dose dipyridamole 
(0.56 mg/kg over 4 min followed 4 min later by an additional 
0.28 mg/kg over 2 min) were evaluated in a multicenter study. 
Planar myocardial perfusion images were obtained at rest and 
after dipyridamole in 101 patients with effort chest pain and no 
prior myocardial infarction. High dose dipyridamole (62 patients) 
was used when typical chest pain or electrocardiographic (ECG) 
signs of ischemia, or both, did not occur during or after the 
standard dose (39 patients). With high dose dipyridamole, 34 
patients had pain (18 patients) or ECG signs of ischemia (ST 
depression ~2 mm) (8 patients), or both (8 patients), whereas the 
other 28 patients had Sestamibi injection in the absence of 
symptoms or ECG changes. 
The dipyridamole test in conjunction with either planar or 
tomographic thallium-201 myocardial petfusion scintigraphy 
is commonly employed to noninvasively assess coronary 
artery disease (1-3). The method has an accuracy similar to 
that observed with exercise stress myocardial scintigraphy 
(4). Recently, a high dose dipyridamole test in conjunction 
with echocardiography was shown to add sensitivity over 
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All patients underwent coronary angiography: 81 had signifi-
cant coronary artery disease (~50% reduction of lumen diameter) 
(affecting one vessel in 38, two vessels in 19 and three vessels in 24 
patients) and 20 patients had normal coronary arteries. The 
overall sensitivity, specificity and predictive accuracy of Sestamibi 
scintigraphy were 81%, 90% and 83%, respectively. No signifi-
cant hypotension, ventricular arrhythmias or other serious ad-
verse reactions occurred in any of the patients tested with the high 
dose dipyridamole; minor side effects occurred in 52% and 57% of 
patients at standard and high dose dipyridamole, respectively, 
and were well tolerated in all. 
In conclusion, Sestamibi scintigraphy associated with high dose 
dipyridamole is an accurate method of evaluating suspected 
ischemic heart disease in patients; it did not result in an increased 
number of side effects as compared with those associated with the 
standard dose protocol. 
(JAm Coli Cardio/1991;18:1439-44) 
that of the standard dose in the detection of ischemic heart 
disease without any loss in specificity or increased risk to the 
patients (5,6). A higher dipyridamole dose should be more 
likely to result in maximal coronary dilation (7), with a larger 
blood flow discrepancy between normally and abnormally 
petfused regions. This may also increase the chances for the 
''steal phenomenon'' from the subendocardial to the subepi-
cardial layers (8). Greater differences in regional myocardial 
blood flow are the requisite for better identification of 
defects using myocardial petfusion scintigraphy. 
A new petfusion tracer, technetium-99m hexakis 2-meth-
oxy-2-isobutyl isonitrile (Sestamibi), was recently intro-
duced for clinical use (9). Technetium-99m is ideal for 
gamma camera imaging, is readily available and its short 
half-life (6 h) allows injection of doses higher than that of 
thallium-201 and the subsequent higher image count density. 
Exercise stress Sestamibi planar and tomographic scintigra-
0735-1097/91/$3.50 
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phy has demonstrated an accuracy similar to that of thal-
lium-201 scintigraphy in the detection of coronary artery 
disease (10, 11). 
In this multicenter study we evaluated feasibility, accu-
racy, and safety of a high dose dipyridamole test in conjunc-
tion with Sestamibi scintigraphy in the detection of coronary 
artery disease in patients with suspected ischemic heart 
disease and no prior myocardial infarction. 
Methods 
Study patients. A total of 101 patients (81 men and 20 
women; mean age 55 ± 9 years) from seven Italian institu-
tions (see Appendix) were enrolled in the study. All had 
suspected coronary artery disease and a history of either 
atypical or typical effort chest pain. Patients with prior 
myocardial infarction, unstable angina, heart failure, severe 
hypertension, valvular or other cardiac disease, age >70 
years, chronic obstructive pulmonary disease, asthma or 
receiving long-term aminophylline therapy were excluded 
from the study as were patients with prior coronary angio-
plasty or coronary bypass surgery. Therapy with calcium 
channel blocking agents and long-acting nitrates was discon-
tinued at least 24 h before each test. Beta-adrenergic block-
ing agents were withdrawn 48 h earlier. The study protocol 
and the use of Sestamibi were approved by the local Ethics 
and Radiation Committees on Human Research. Informed 
consent was obtained from all patients. 
Exercise stress test. An upright bicycle multistage stress 
test was performed. The work load was increased by 25 W 
every 2 min; three electrocardiographic (ECG) leads (V 1, V 5, 
a VF) were continuously monitored throughout the test and 
12-lead ECG and blood pressure measurements were ob-
tained every minute. The test was interrupted because of 
diagnostic ST segment depression in 52 patients, progressive 
typical chest pain without ECG signs of ischemia in 15 and 
either excessive fatigue or achievement of the maximal 
age-predicted heart rate in 26. In eight patients, the test was 
not performed. According to the criteria of Diamond and 
Forrester (12), the pretest probability of coronary artery 
disease was <30% in 5 patients (5%) with no ST segment 
change and no anginal pain or other symptoms; between 30% 
and 75% in 53 patients (52%), including 36 patients with 
atypical or typical pain with negative or borderline ST 
segment shift and 13 patients with asymptomatic ST segment 
depression; and >75% in 43 patients (43%) with ST segment 
depression and typical chest pain. The mean rate-pressure 
product at baseline and at peak exercise was 9,906 + 2,340 
and 23,793 + 5,576, respectively (p < 0.001). 
Angiographic study. All patients underwent coronary 
angiography and biplane (30° right anterior and 40° left 
anterior oblique projections) contrast ventriculography per-
formed with either the Judkins or the Sones technique. The 
quantitative estimation of coronary stenosis was not avail-
able in all seven participating centers; therefore, coronary 
anatomy and wall motion were qualitatively evaluated by 
two independent observers unaware of clinical and scinti-
graphic results. Coronary stenosis was considered signifi-
cant in the presence of 2:50% narrowing of luminal diameter. 
Regional wall motion was scored as normal, hypokinetic, 
akinetic or dyskinetic. Differences, when present, were 
resolved by a third observer. The angiographic study was 
performed in all patients within 3 weeks of the scintigraphic 
evaluation. 
Dipyridamole test. The test was performed after over-
night fasting. Patients were instructed to avoid coffee or tea 
for 2:3 h before the test. Three ECG leads (V ~> V 5, a VF) 
were continuously monitored throughout the test and a 
12-lead ECG and blood pressure were recorded before and 
every minute after starting the infusion. 
Dipyridamole (Persantine, Boehringer-Ingelheim) was 
administered intravenously at a dose of 0.56 mg/kg in 4 min 
(standard dose). The test was discontinued in the presence of 
>0.2 mY horizontal or downsloping ST segment depression 
0.08 s after the J point or angina-like chest pain. In the 
absence of either ECG signs of ischemia or symptoms, an 
additional dose of 0.28 mg/kg of dipyridamole (high dose) 
was administered after a 4 min interval over 2 min (cumula-
tive dose 0.84 mg/kg over 10 min). Aminophylline (80 to 
240 mg over 2 min), which promptly reverses the effect of 
dipyridamole, was given, when clinically possible, not ear-
lier than 4 min after Sestamibi injection. Nitrates were also 
ready for immediate use. 
Sestamibi myocardial scintigraphy. Sterile pyrogen-free 
Sestamibi (Cardiolite, E.l. du Pont de Nemours Co.) was 
prepared by adding a maximum of 80 mCi of sodium pertech-
netate solution (2 to 3 ml) to the kit; the vial was then placed 
in a shielded boiling water bath for 10 min. Labeling effi-
ciency was tested by thin layer chromatography before the 
injection. Radiochemical purity was >95% in all cases. The 
tracer (15 to 20 mCi, 555 to 740 MBq) was injected in patients 
with symptoms or a positive ECG, or both. In those with a 
negative ECG, the tracer was injected 3 min after the 
completion of the high dose of dipyridamole. Rest Sestamibi 
study was performed 2:24 h later with the patient in the 
fasting condition. Approximately 20 min after both stress 
and rest Sestamibi injection, patients ate a light meal to 
accelerate hepatobiliary clearance of the tracer. 
Three planar images (anterior and 40° and 70° left anterior 
oblique projections) were obtained during baseline condi-
tions and after dipyridamole within 60 to 90 min after tracer 
administration using a 128 x 128 matrix. Either large field 
(Starcam 2000, G.E., two centers) or small field (Apex 
210-M, Elscint, five centers) mobile cameras were used, 
equipped with low energy, high resolution, parallel hole 
collimators and with a 20% energy window centered on the 
140-keV photopeak of technetium-99m. At least 800,000 
counts were collected for each acquisition, with a hardware 
magnification factor of 1.3. All images were stored on 
magnetic disk for subsequent analysis. 
Image analysis. The two sets of images (dipyridamole and 
rest) were displayed as raw data images side by side for 
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Figure 1. The three Sestamibi projections, together with the relative 
territory distribution of the coronary arteries, are displayed. The 
apical segment was assigned to a specific territory according to the 
perfusion pattern of the adjacent areas. 
interpretation. Each projection was divided into five sec-
tions, according to the segmental analysis of thallium-20I 
scintigraphy. The perfusion pattern was evaluated in each 
center by two independent observers unaware of clinical and 
angiographic results, using a 4-point scoring system (3 = 
normal perfusion, 2 = slightly reduced, I = severely reduced 
and 0 = absent). From the comparison between dipyrida-
mole and control images, each segment was graded as 
normal with a reversible or fixed defect. 
The anterolateral wall (segments 10 and II), interventric-
ular septum (segments I and 2) and the anterior wall (seg-
ments 8 and 9) were considered to be supplied by the left 
anterior descending artery; the inferior wall (segments 6, I2 
and 13) was considered to be a territory of the right coronary 
artery and the posterolateral (segments 4 and 3) and poste-
rior wall (segment 5) were considered to be supplied by the 
circumflex artery (Fig. 1). The apical segment (segment 7) 
was assigned to a specific territory according to the perfu-
sion pattern of the adjacent segments. 
In a random sample of 390 segments in 30 patients 
collected for the evaluation of interobserver agreement 
among the centers, there was agreement regarding the clas-
sification of segments into normal and reversible or fixed 
defect in >85% of the segments. 
Statistical analysis. Statistical analysis was performed by 
using analysis of variance or the two-tailed Student's t test 
Table 1. Angiographic Findings in the 101 Patients With Effort 
Chest Pain 
Regional wall motion abnormalities 
LV ejection fraction (mean± SD) (%) 
Normal "smooth" vessels 
No significant (<50%) stenosis 
Significant (50% to 70%) stenosis 
Critical (> 70%) stenosis 
LV = left ventricular. 
No. of Patients 
40 of 86 
64 ± 9 
19 
I 
6 
75 
for paired data as appropriate. Chi-square analysis was used 
for comparison of proportions. Data are expressed as mean 
values ± I SD. A p value <0.05 was considered significant. 
Results 
Coronary anatomy and ventricular function (Table 1). 
Significant coronary artery stenosis was observed in 8I pa-
tients (by unanimous agreement in 75 and by consensus with a 
third observer in 6). One-, two- and three-vessel disease was 
observed in 38, I9 and 24 patients, respectively. The left main 
coronary artery was involved in five patients, all with triple-
vessel disease. Coronary arteries were unanimously judged as 
normal in 19 patients and by consensus with a third observer in 
I. Ventricular function was normal in 46 patients and showed 
regional dyssynergy in 40. In I5 patients, contrast ventriculog-
raphy was not performed or was of unsatisfactory quality. 
Mean left ventricular ejection fraction was 64 ± 9%. The 
angiographic results are shown in Table I. 
Clinical responses to dipyridamole. Administration of the 
standard dipyridamole dose yielded typical symptoms or 
ECG signs of ischemia, or both, in 39 patients. Sixty-two 
patients required additional administration of dipyridamole 
(high dose). Chest pain and ECG changes after standard and 
high dose dipyridamole were correlated with the angio-
graphic findings (Table 2). The sensitivity of ECG changes 
and symptoms in the detection of coronary artery disease 
was 46% and 62%, respectively; specificity was 75% and 
60%, respectively. For comparison, the exercise stress test 
showed a sensitivity and specificity in the detection of 
coronary artery disease of 59% and 58%, respectively. 
The rate-pressure product at baseline and at the time 
of Sestamibi injection was 9,700 ± 2,50I and 13,629 ± 
3,364 mm Hg x beats/min, respectively (p < 0.001). Eighty-
five patients required aminophylline, which was adminis-
tered a mean of 4 ± 3 min after injection of the tracer; no 
patient required nitrates. Aminophylline was given to 73 
patients because of the occurrence of either ECG signs of 
ischemia or chest pain and to I2 patients to reverse the side 
effects of dipyridamole. 
Detection of coronary artery disease. Sestamibi scintigra-
phy correctly identified perfusion defects in 66 of the 8I 
patients with coronary artery disease and disclosed no 
perfusion defects in I8 of the 20 patients with normal 
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Table 2. Electrocardiographic (ECG) Signs and Symptoms (Pain) of Ischemic ~eart Disease After the Standard and the High Dose 
Dipyridamole Test: Correlation With Angiographic Data on Coronary Artery Dtsease 
Standard Dose (n = 39) High Dose (n 62) 
OVD IVD 2VD 3VD OVD IVD 2VD 3VD 
No. of patients 6 16 7 10 14 22 12 14 
ECG I 2 3 3 3 I 
Pain 2 6 2 3 7 3 
ECG+pain 8 4 4 2 2 4 
No ECG or pain 10 10 2 6 
OVD, IVD, 2VD and 3VD = angiographic findings of coronary artery disease in zero, one, two or three vessels, respectively. 
coronary arteries or an insignificant lesion. Overall sensitiv-
ity and specificity in the detection of coronary artery disease 
were 81% and 90%, respectively. Positive and negative 
predictive values were 97% and 54%, respectively; the 
overall predictive accuracy was 83%. The sensitivity of the 
technique in one-, two- and three-vessel disease was 68%, 
100% and 87%, respectively. 
In patients with coronary artery disease, myocardial 
scintigraphy showed a fixed perfusion defect in 8 patients, a 
reversible defect in 16 and both a reversible and a fixed 
defect in 42. A partially reversible perfusion defect was 
observed in two patients with no coronary artery disease. 
Severity and diseased vessel identification (Tables 3 and 4). 
A total of 148 stenotic vessels were identified by coronary 
angiography. Sestamibi scintigraphy correctly identified 103 
(70%) of 148 diseased vessels and 131 (85%) of the 155 
normal coronary arteries. The sensitivity and specificity of 
Sestamibi scintigraphy in detecting individual coronary ar-
tery stenosis are presented in Table 3. 
Perfusion abnormalities in segments corresponding to one 
vascular region were detected in 11 (29%) of the 38 patients 
with one-vessel disease. The technique overestimated the 
extent of coronary atherosclerotic involvement in 15 patients 
(39%). In the 43 patients with multivessel disease, perfusion 
defects in more than one vascular region were observed in 34 
patients (79%); in the other 9 patients, scintigraphy under-
estimated the extent of coronary artery disease (single-
vessel diagnosis) in 6 patients (14%) and showed normal 
findings in 3 (7%) (Table 4). 
Side effects. No significant hypotension, arrhythmias or 
other serious adverse reactions occurred in any patient after 
either the standard or the high dose of dipyridamole. Minor 
side effects (headache, mild transient facial flushing, nausea) 
occurred in 52% and 57% of patients receiving the standard 
and the high dose, respectively (p = NS). 
Table 3. Sensitivity and Specificity of Sestamibi Scintigraphy for 
Identifying Vessel With Disease 
Sensitivity Specificity 
LAD 60 75 
LCx 68 82 
RCA 65 84 
LAD = left anterior descending artery; LCx = left circumflex artery; 
RCA = right coronary artery. 
Discussion 
Patient selection. In this multicenter study, planar Sesta-
mibi scintigraphy was used for the first time with the high dose 
dipyridamole test in the assessment of coronary artery dise~~e. 
Our results indicate that this approach provides good sensitiv-
ity and specificity and is safe when appropriately used. 
The protocol design allowed us to minimize bias in patient 
selection and to collect a relevant number of subjects suit-
able for statistical analysis in a reasonably short period. In 
addition, the selection criteria permitted us to assess the 
diagnostic power of the high dose dipyridamole test with 
planar Sestamibi scintigraphy in a group of patients ~ith an 
intermediate pretest probability of coronary artery disease. 
Indeed, according to the definition of Diamond and Forrester 
(12) for pretest likelihood of disease, >50% of patients 
enrolled in our study had a pretest probability ranging from 
30% to 75%; thus, according to Bayes' theorem (13), in these 
patients the use of additional tests should help diagnose the 
disease. 
As a limitation of the present study, the multicenter 
design did not allow quantitative computerized measure-
ments of coronary lesions. The qualitative assessment of 
coronary stenosis might have altered the values of sensitiv-
ity, specificity and accuracy of Sestamibi scintigraphy. How-
ever, the purpose of this study, beyond the estimation of 
functional severity of coronary lesions, was to identify those 
patients with coronary artery disease. In fact, only seven 
patients (7%) showed 20% to 70% reductio~ of lumin~l 
diameter in a single vessel; in all seven, differences m 
assessment of disease were resolved by a third observer. 
Comparison with single-photon emission computed tomog-
raphy. With this approach, 81% of patients with coronary 
artery disease were identified. These results favorably com-
pare with those obtained by using Sestamibi single-photon 
Table 4. Accuracy of Sestamibi Scintigraphy in Identifying the 
Extent of Coronary Artery Disease 
No. of Abnormal Sestamibi Territories 
0 
OVD (n = 20) 18 
IVD (n = 38) 12 
2 or 3VD (n = 43) 3 
Abbreviations as in Table 2. 
II 
6 
2 or 3 
15 
34 
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emission computed tomography in conjunction with an ex-
ercise test. Kiat et al. (11) showed that the overall sensitivity 
and specificity for identification of coronary artery disease 
with planar Sestamibi imaging were not statistically different 
from those obtained with single-photon emission computed 
tomographic imaging. However, single-photon emission 
computed tomography proved to be superior to planar 
Sestamibi imaging for the identification of individual dis-
eased vessels. Single-photon emission computed tomo-
graphic technology could not be used for practical reasons in 
our multicenter study. Further trials will be necessary to 
establish whether the tomographic approach combined with 
the high dose dipyridamole test would provide better results 
than those obtained in our study. 
Rationale for high dose dipyridamole. No important side 
effects were reported (14) in a large series of patients with 
suspected ischemic heart disease evaluated by high dose 
dipyridamole echocardiography. This approach has also 
been used after the acute phase of myocardial infarction; no 
major adverse cardiac events occurred as a result of the 
procedure in the study of Bolognese et al. (15). However, it 
is not clear whether high dose dipyridamole scintigraphy 
would provide sufficient additional diagnostic information to 
justify its use over the conventional dose. Perfusion scintig-
raphy in conjunction with the dipyridamole test has been 
widely employed since 1978 (2) to evaluate abnormal coro-
nary flow reserve in ischemic heart disease. The sensitivity 
of dipyridamole imaging for the detection of coronary artery 
disease >80% when the standard dose is used (16,17). These 
high values can be explained by patient selection, which 
included patients with either a high likelihood of disease or 
previous myocardial infarction. We attempted to overcome 
this bias, enrolling patients who were referred to the seven 
centers because of a chest pain syndrome suggestive of 
ischemic heart disease. With use of these selection criteria, 
a high positive predictive value (97%) in the detection of 
coronary artery disease was achieved by high dose dipyrid-
amole scintigraphy. Because of the study design, a direct 
comparison between the diagnostic accuracy of standard and 
high dose dipyridamole Sestamibi scintigraphy was not 
feasible. In fact, we could not compare the scintigraphic 
results of the two subgroups (standard vs. high dose) be-
cause: 1) the patient groups were different, likely to have 
different degrees of impairment of coronary flow reserve; 
and 2) we could not know the perfusion and scintigraphic 
pattern at the standard dose in patients who received the 
high dose of dipyridamole and vice versa. Moreover, the 
different criteria in patient selection prevent comparisons 
with previous reports on the standard dose of dipyridamole. 
The rationale for the dipyridamole test is based on the 
maldistribution of regional blood flow induced by pharma-
cologic vasodilation in patients with coronary artery disease 
(1); in addition, increasing the blood supply to a normally 
perfused territory may result in "coronary steal" from areas 
supplied by the stenotic vessel (7, 18). More recently, tech-
niques capable of measuring coronary reserve in humans 
demonstrated that the conventional dose of dipyridamole 
(0.56 mg/kg over 4 min) does not consistently induce maxi-
mal coronary vasodilation (7, 19). Therefore, a higher dose of 
the drug has been clinically employed to achieve maximal 
dilation of the small coronary vessels, increasing the chances 
for the steal phenomenon (6). The use of perfusion tech-
niques to assess coronary flow maldistribution does not 
necessarily require the occurrence of "true ischemia" (20); 
however, greater vasodilation facilitates discrepancies in 
regional tracer uptake between normally and abnormally 
perfused regions and allows better identification of perfusion 
defects. The high dose dipyridamole test results in an 
increased occurrence of ischemia as compared with the 
standard dose in the same patients (6). It is also likely that 
this would result in increased detection of perfusion defects 
by myocardial scintigraphy. However, these assumptions 
must take into account the kinetic characteristics of liquid 
deposit tracers such as Sestamibi (21). Tracer uptake de-
pends on flow and extraction rates (net extraction); accord-
ing to the Renkin-Crone relation, at high flow, the extraction 
fraction decreases and the linearity of the correlation be-
tween uptake and flow is no longer maintained (22,23). 
Whether high dose dipyridamole would result in a Sestamibi-
related myocardial net extraction higher than that obtained 
with the lower dose has still to be demonstrated. 
Perfusion defects at rest. Despite the exclusion of patients 
with clinical or ECG evidence of prior myocardial infarction, 
or both, 50 (62%) of the 81 patients with coronary artery 
disease showed a fixed perfusion defect. This number is 
somewhat higher than that previously reported for Sestamibi 
(10, 11) and poses problems of interpretation on tracer kinet-
ics and uptake in the presence of a fixed obstructive coro-
nary lesion. Such a high incidence of perfusion abnormalities 
at rest cannot be explained by the presence of previous non-Q 
wave silent infarction. Thirty of these 50 patients had multives-
sel disease and 28 had regional wall motion abnormalities on 
contrast ventriculography. A possible alternative explanation 
is that basal Sestamibi scintigraphy would have identified most 
of the patients with multi vessel disease (30 of 43) and regionally 
exhausted coronary flow reserve. This "chronic" hypoperfu-
sion could have been responsible for a perfusion defect at rest 
on Sestamibi scintigraphy, which was associated with angio-
graphically documented myocardial dyssynergy in 28 patients, 
a clinical condition that meets the definition of hibernating 
myocardium. In the remaining 22 patients, regional wall motion 
was angiographically normal, possibly indicating lesser, if any, 
impairment of myocardial contractility caused by rest hypo-
perfusion. Whether the kinetic characteristics of this tracer 
(namely, fast blood pool clearance, negligible myocardial 
washout) might facilitate detection of myocardial regions with 
exhausted coronary flow reserve compared with basal thai-
Iium-201 scintigraphy is a matter of investigation. It is now 
evident that Sestamibi and thallium-201 have a different behav-
ior and fate once inside myocardial cells (24). Accordingly, 
identification of a basal perfusion defect on myocardial scintig-
raphy with the presence of myocardial scar, a synonym cur-
rently used in thallium-201 imaging, should be cautiously 
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employed when perfusion at rest is assessed with Sestamibi 
scintigraphy. 
Safety. No patient enrolled in the study experienced 
severe side effects as a consequence of high dose dipyrida-
mole administration. The prompt use of aminophylline at the 
occurrence of typical pain, diagnostic ST segment shift or 
other side effects was recommended in all centers because of 
the potential ischemic effect of dipyridamole infusion de-
scribed in previous reports (5,6). The potential decrease in 
sensitivity caused by the early normalization of flow discrep-
ancies after aminophylline was therefore counterbalanced by 
a safer use of the test. However, as shown in the Results, the 
ECG and symptoms do not represent optimal indicators for 
the application of the enhanced drug dose. In the absence of 
a more reliable marker of an optimal pharmacologic effect of 
dipyridamole on the coronary circulation, the use of the 
enhanced drug dose appears to be supported by the compa-
rable safety of the test at the standard and high doses and by 
the similar incidence of side effects. From a practical point of 
view, optimal pharmacologic coronary vasodilation has been 
achieved by this approach (7, 19) without loss of safety. 
Conclusions. Sestamibi myocardial scintigraphy associ-
ated with a high dose dipyridamole test has proved to be an 
effective, accurate and safe method for diagnosing coronary 
artery disease in patients with a chest pain syndrome, a 
clinically stable condition and no prior myocardial infarc-
tion. This approach provides good accuracy for planar 
imaging and favorably compares with the echocardiographic 
technique for the detection of ischemic heart disease. Direct 
comparison of the two techniques associated with high dose 
dipyridamole will further clarify the role of the two methods 
in the evaluation of patients with ischemia. 
Appendix 
Participating Centers 
Istituto di Fisiologia Clinica del CNR. Pisa, Italy: 0. Parodi. MD. 
C. Marcassa, MD, P. Marzullo, MD, G. Sambuceti. MD. L. Donato, MD. 
Dipartimento Cardiologico Centro De Gasperis e Servizio di Medicina 
Nucleare. Ospedale Niguarda. Milano, Italy: E. Inglese. MD. S. Pirelli, MD, 
C. De Vita, MD, F. Spinelli, MD. 
Fondazione Clinica Del Lavoro. Veruno (NO), Italy: M. Galli. MD, 
L. Tavazzi, MD. 
Dipartimento Cardiologico R. Donatelli, Ospedale di Circolo, Varese, Italy: 
E. Verna, MD, R. Casucci, MD, G. Binaghi, MD. 
Istituto di Fisiopatologia Clinica e Sezione di Medicina Nucleare, Ospedale 
di Careggi, Florence, Italy: G. Bisi, MD, U. Meldolesi, MD. 
Servizio di Medicina Nucleare, Spedali Civili, Brescia, Italy: R. Giubbini, 
MD, M. Bestagno, MD. 
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